Humulin M3 (30/70)

Humulin M3 (30/70) is an injectable suspension of insulin human, a short‑acting and intermediate‑acting insulin mixture used in the European market. It contains recombinant human insulin at a 30% rapid‑acting and 70% protamine‑crystallized proportion, providing both immediate and prolonged glucose‑lowering effects. The product is prescription‑only and administered subcutaneously. It is supplied in vials for use with a syringe, and it is intended for patients requiring basal‑bolus insulin therapy.

Humulin M3 (30/70) is prescribed to help control blood glucose levels in adults and children with diabetes.

- For both type 1 and type 2 diabetes mellitus when a mixed insulin regimen is appropriate. - As the basal (long‑acting) component of a basal‑bolus insulin therapy plan. - In patients who require a predictable overnight and fasting glucose control. - When combined with rapid‑acting insulin analogues to cover mealtime carbohydrate intake. - As an adjunct to oral antidiabetic drugs in type 2 diabetes when additional glucose lowering is needed.

The most frequently reported adverse reactions to Humulin M3 (30/70) are related to its glucose‑lowering action and injection site.

Common: - Hypoglycemia, presenting as sweating, tremor, hunger, or confusion. - Redness, swelling, or itching at the injection site. - Transient weight gain due to increased glucose storage. - Lipodystrophy, such as localized lipoatrophy or lipohypertrophy. - Mild peripheral edema.

Serious: - Severe hypoglycemia with loss of consciousness or seizures. - Immediate hypersensitivity reactions, including urticaria or angioedema. - Anaphylactic shock, a life‑threatening allergic response. - Development of insulin antibodies that may alter insulin action. - Significant electrolyte disturbances such as hypokalemia.

Before initiating therapy with Humulin M3 (30/70), several safety considerations should be reviewed to minimize risk.

- Verify blood glucose levels and adjust dose to avoid hypoglycemia. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Monitor pregnant or breastfeeding women closely; insulin requirements often change during these periods. - Assess for a history of allergic reactions to human insulin or excipients. - Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy. - Consider dose adjustments during periods of illness, surgery, or changes in physical activity. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 (30/70) can interact with other medicines, affecting blood glucose control or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulin analogues without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that blunt hypoglycemia warning signs.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk. - Corticosteroids, which raise blood glucose and may require higher insulin doses. - Diuretics, especially thiazides, that can affect potassium levels and insulin sensitivity. - ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect. - Alcohol, which can cause delayed hypoglycemia after insulin administration.